Also at the National Institute for Arthritis and Musculoskeletal and Skin Diseases, we have a study of 1588 subjects being enrolled in 13 centers asking whether glucosamine or chondroitin sulfate, alone or in combination, are superior to placebo and might be as good as the current main therapy, cyclooxygenase II inhibitors (COX-2).

And with the National Cancer Institute, we’re privileged to help support a 32,000 patient study for prevention of prostate cancer with Vitamin E and selenium.

With the National Heart, Lung and Blood Institute, we are about to award a major multi-center trial for the first time of ETDA chelation therapy for coronary artery disease. And with the National Institute for Diabetes and Digestive and Kidney Disorders, we have called for applications to study two of the world’s most popular herbal products for the treatment of prostatic enlargement, which many men in my age begin to consider as a health factor.